Cyprumed's Oral Peptide Tablet Technology Enters Human Clinical Development As MSD Initiates Phase I Trial, Triggering Milestone Payment For Up To $493M From MSD

Benzinga · 2d ago
  • The Phase I clinical trial will evaluate a proprietary drug candidate formulated using Cyprumed’s oral tablet technology, marking the first Cyprumed technology program to enter human clinical development
  • The milestone triggers a payment to Cyprumed under the companies’ existing collaboration agreement